Cambridge Heart Announces New Research and Development Initiative

Derivative of core MTWA Technology may be used to identify patients with undetected coronary artery disease

• Press Release
• Source: Cambridge Heart, Inc.
• On 4:35 pm EDT, Wednesday September 23, 2009

TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology. The Company has gathered data, which although limited and preliminary, suggests that a variant of its core spectral analytic method of measuring Alternans may be able to identify myocardial ischemia which is otherwise largely undetected by more established cardiac diagnostic testing. Ischemia is defined as inadequate blood supply due to blockage of coronary arteries and can lead to myocardial infarction or what is commonly referred to as a “heart attack.” The Company’s current MTWA technology is focused on identifying those patients at risk for Sudden Cardiac Arrest (SCA) resulting from electrical disturbances in the heart.

Related Quotes

Symbol	Price	Change
CAMH.OB	0.08	+0.01

{"s" : "camh.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“We have been examining the preliminary data and it appears that, in a number of instances, a positive Alternans reading correlated with the presence of myocardial ischemia, where the traditional cardiac stress test did not indicate anything abnormal, said Ali Haghighi-Mood, Cambridge Heart’s Chief Executive Officer. The physiologic link between ischemia and alternans is well-established in the experimental setting. If our modified Alternans technology can identify hidden ischemia in patients with suspected coronary artery disease, we believe it could set a new standard for the diagnostic performance of cardiac stress testing, which has undergone very little clinical innovation in many years.”

The Company has filed a provisional patent on the ischemia application and intends to file a full patent before the end of the year. The design of an initial pilot study is underway, and the Company expects to be in a position to initiate the study in the first half of 2010. It is estimated that up to 40 million cardiac stress tests are performed annually in the United States.

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans™ measurement technologies, including the patented Analytic Spectral Method^® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company’s MTWA technology, failure to raise new capital resources necessary to support our operations and to develop or enhance our technology, failure to initiate and conduct successfully new clinical trials and studies involving our technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure to obtain or maintain adequate levels of first-party reimbursement for use of the Company's MTWA test, customer delays in making final buying decisions, decreased demand for the Company's products, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.

At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
vincenzol@cambridgeheart.com
or
Media:
KOGS Communication
Edna Kaplan, 781-639-1910
kaplan@kogspr.com
or
Investor Relations:
Allen & Caron
Matt H. Clawson, 949-474-4300
matt@allencaron.com